The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC).
Ann-Lii Cheng
Consultant or Advisory Role - Boehringer Ingelheim
Gerardo H. Cornelio
No relevant relationships to disclose
Lin Shen
No relevant relationships to disclose
Timothy Jay Price
Consultant or Advisory Role - Merck KGaA (U)
Tsai-Shen Yang
No relevant relationships to disclose
Ik-Joo Chung
No relevant relationships to disclose
Guanghai Dai
No relevant relationships to disclose
Jen-Kou Lin
No relevant relationships to disclose
Atul Sharma
No relevant relationships to disclose
Kun-Huei Yeh
No relevant relationships to disclose
Brigette Ma
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
Research Funding - Merck Serono
Adel Zaatar
No relevant relationships to disclose
Zhongzhen Guan
No relevant relationships to disclose
Nehal Masood
No relevant relationships to disclose
Vichien Srimuninnimit
No relevant relationships to disclose
Thomas Cheung Yau
No relevant relationships to disclose
Barbara Sarholz
Employment or Leadership Position - Merck KGaA
Robert S.C. Lim
Consultant or Advisory Role - Merck Serono